Oncology Drug Discovery
Charles River’s experience with oncology drug discovery spans all phases, from target identification to IND studies. Utilizing the most effective combination of tools available to identify promising compounds, we work with our partners to design studies by selecting from amongst a broad range of well-characterized xenograft, patient-derived xenograft (PDX), and syngeneic tumor models. Combining those models with appropriate biomarkers, including flow cytometry and imaging, allows our partners to choose the most appropriate study design and screening method to identify promising compounds and optimize lead candidates.
Charles River can aid oncology drug discovery across a range of modalities including small molecules, immune therapies, biologics, cell therapies, and our BSL2 facilities allow us to work with various viral vectors and cancer vaccines. Each of our models are supported by a range of translational tools including ELISpot, flow cytometry, and imaging.
AACR Posters Now Available
Check out our scientific posters from the AACR Annual Meeting 2019 in Atlanta, Georgia.
Download Here
Available Oncology Models/Studies
- Human tumor xenografts (mice)
- Patient-derived xenografts (PDX)
- Syngeneic models
- Humanized mice
- Single mouse trials
- Orthotopic models
- Human tumor xenografts (rats)
- Angiogenesis models
- Cachexia models
- Radiation
- Neurotoxicity
- Immuno-oncology Pharmacodynamic Models
|
|
|---|
|
|
Charles River’s Oncology Fast 5, is a scientist-curated skim of industry articles, blog posts, data, and interactive content covering hot topics in cancer research. Sign up
UPCOMING EVENTS
Bioinformatics: Leveraging the Molecular Landscape to Drive Oncology Discovery
Oct. 23, 2019 | Online Webinar
Reserve your Seat
Harnessing The Entire Immune System
Oct. 24-25th, 2019 | Cambridge, MA
Learn More